Skip to main
  1. Stocks
  2. Astrana Health Inc
  3. Forecast
ASTH

ASTH Stock Forecast & Price Target

ASTH Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Astrana Health is supported by strong execution in value-based care, with 3Q26 revenue of $1,023.6mm, adjusted EBITDA of $77.2mm, and gross margin expanding 190bps to 12.1%, while Care Partners remained the largest growth engine at $968.8mm, up 7.9% Y/Y. Its outlook is reinforced by favorable medical cost trend running below the ~5.2% assumption, ~82% of capitation expected in full-risk by year end, and ACO results showing $120.4mm in gross shared savings across 8 ACOs, evidence that its model can manage risk and generate savings. Management also remains conservative, narrowing FY26 guidance while leaving midpoints unchanged and continuing to reinvest in growth, which suggests further upside as Medicare strength, new payor partnerships, and higher-risk contracting flow through.

Bears say

Astrana Health is exposed to a fragile earnings profile because the bear case assumes unfavorable cost trends that compress FY27 adjusted EBITDA growth, while its model remains dependent on third-party reimbursement and a heavily regulated healthcare environment. Competitive pressure also looks meaningful, as larger and better capitalized players can expand their reach in population health and digital health, making it harder for Astrana to defend share and sustain operating momentum. The cited CVS Health ACO REACH data underscore the challenge in the broader market, where ~$3.2B in spending still produced only a 3% savings rate and an 83% quality score, highlighting how difficult it may be for Astrana to deliver consistently strong economics.

ASTH has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.

ASTH Analyst Forecast & Price Prediction

Get the latest ASTH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ASTH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Astrana Health Inc (ASTH) Forecast

Analysts have given ASTH a Strong Buy based on their latest research and market trends.

According to 9 analysts, ASTH has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.78, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.78, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Astrana Health Inc (ASTH)


ASTH Analyst Forecast & Price Prediction

Get the latest ASTH stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ASTH

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ASTH stock data and trends